PARP1 and posterior cortical atrophy: These studies not only further solidify PARP‐1 as a therapeutic target in the management of PCa, but nominate PARP‐1 activity as a potential biomarker, and PARP‐1 inhibition as a mechanism to induce or enhance BRCA‐ness.